摘要
目的：评价莫比可治疗类风湿关节炎（ＲＡ）的临床疗效及其安全性。方法：采用随机对照的方法将受试者分为：莫比可组和奇诺力组，受试者口服莫比可１５ｍｇ，１次／ｄ，或口服奇诺力２００ｍｇ，２次／ｄ，疗程均为４周，对比治疗前和疗程结束时患者的关节疼痛个数，疼痛、压痛和肿胀指数、晨僵持续时间、握力、血沉和Ｃ－反应蛋白等指标变化，并作出疗效评价。结果：治疗后除两组关节疼痛个数和莫比可组握力未获显著改善外（Ｐ＞０．０５），其余观察指标均获显著改善（Ｐ＜０．０１或Ｐ＜０．０５）。显效率在莫比可组和奇诺力组分别为２９．２％与３３．３％；总有效率：莫比可组为７０．９％，奇诺力组为７７．７％。副反应发生率两组均为１６．７％，服用方便，仅每日１次，无撤药者。结论：莫比可治疗ＲＡ疗效确切，副作用小，同奇诺力相比较，疗效和副作用差异均无显著性意义。
Objective:A randomized and controlled study was conducted in patients with rheumatoid arthritis (RA) in order to assess the efficacy and safety of mobic.Methods: The patients were randomized to receive once daily oral mobic 15 mg ( n =24) or clinoril 200 mg twice daily ( n =18) for 4 weeks. Results: After treatment, all the observed parameters were significantly improved in both groups ( P <0 01 or P <0 05), except the number of painful joints in both groups and grip strength in mobic group ( P >0 05). The rates of marked improvement were 29.2% and 33.3% in mobic and clinoril respectively. The rate of side effects in both groups was 16.7%. Conclusion: Mobic is well tolerated and effective in treatment of patient with RA. The efficancy and side effects are just the same in both groups.
出处
《军医进修学院学报》
CAS
1999年第2期92-94,共3页
Academic Journal of Pla Postgraduate Medical School
